NAYA Biosciences Announces Strategic Decision to Separate Fertility and Oncology Businesses into Distinct Operations – Company Renamed “INVO Fertility, Inc.”

Apr 14, 2025 | Press Releases

Public company to operate under new name and concentrate on building, acquiring and operating fertility clinics and the distribution of FDA-cleared INVOcell device Private company to operate as NAYA Therapeutics and focus on clinical development of bifunctional...

NAYA Announces a 1:12 Reverse Stock Split Effective Pre-Market Opening on March 18, 2025

Mar 13, 2025 | Press Releases

SARASOTA, Fla. and MIAMI, March 13, 2025 — NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, and a...

NAYA Biosciences Supports Recent Executive Order Aimed at Improving Access to Fertility Treatment

Feb 25, 2025 | Press Releases

NAYA Sees Potential Positive Impact to Its Existing Fertility Operations and FDA-Cleared INVOcell TechnologySARASOTA, Fla. and MIAMI, Feb. 25, 2025 — NAYA Biosciences, Inc. (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to...

NAYA Biosciences Announces Nomination of New Board Members

Feb 19, 2025 | Press Releases

New board reflects company’s added focus on oncology & autoimmune diseases SARASOTA, Fla. and MIAMI, Feb. 19, 2025 — NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to...

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering

Jan 13, 2025 | Press Releases

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 — NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health, today announced...

NAYA Biosciences Announces Development of NY-500, a Novel AI-Optimized PD-1 x VEGF Bifunctional Antibody

Jan 6, 2025 | Press Releases

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 — NAYA Biosciences (“NAYA”)...